Form 483 Docks Clinical Formula for Inadequate Quality and Laboratory Controls

The FDA issued skincare drug product developer Clinical Formula a five-observation Form 483 for lacking an effective quality control unit and other serious deficiencies observed during a November-December 2021 inspection of its Newport Beach, Calif., facility.
Source: Drug Industry Daily